Based on our current understanding, systemic pharmacological inhibition of all PI3K isoforms should enhance the immunogenicity of the pancreatic tumors by upregulating MHC I and CD80, but inhibitory effects on cytotoxic T cells will negate these beneficial changes. This evidence concerns the gene PIK3CA and pancreatic neoplasm.